Athira Pharma Inc
NASDAQ:ATHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Athira Pharma Inc
Pre-Tax Income
Athira Pharma Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Athira Pharma Inc
NASDAQ:ATHA
|
Pre-Tax Income
-$96.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-80%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Pre-Tax Income
$24.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pre-Tax Income
$9.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Pre-Tax Income
$7.5B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Pre-Tax Income
$21.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
29%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Pre-Tax Income
$25.7B
|
CAGR 3-Years
56%
|
CAGR 5-Years
29%
|
CAGR 10-Years
25%
|
|
Athira Pharma Inc
Glance View
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 63 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and stop neurodegeneration. Its pipeline consists of both blood brain barrier (BBB) permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system (PNS), and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. The company is also advancing potential drug candidates for neuropathic pain, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. Its neuropathic pain drug candidate, ATH-1020, completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
See Also
What is Athira Pharma Inc's Pre-Tax Income?
Pre-Tax Income
-96.9m
USD
Based on the financial report for Dec 31, 2024, Athira Pharma Inc's Pre-Tax Income amounts to -96.9m USD.
What is Athira Pharma Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-80%
Over the last year, the Pre-Tax Income growth was 18%. The average annual Pre-Tax Income growth rates for Athira Pharma Inc have been -21% over the past three years , -80% over the past five years .
